AKR1C3 as a potential biomarker for sensitivity of T-lineage acute lymphoblastic leukaemia to the pre-prodrug PR-104

点击翻译按钮获取中文摘要

Multiagent chemotherapy is the most effective modality for the treatment of childhood ALL, the most common paediatric malignancy. Despite dramatic improvements in survival over the past 40 years, relapsed ALL remains one of the most common causes of death from disease in children. Therefore, innovative strategies are needed to benefit those children who respond poorly to established therapy. This application will test a novel therapy for a very aggressive subtype of childhood leukaemia.